Screener
Tango Therapeutics TNGX Unrealized Gains on Investments
Unrealized Gains on Investments at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
FAQ
- What is Tango Therapeutics's unrealized gains on investments?
- Tango Therapeutics (TNGX) reported unrealized gains on investments of $19K in Q1 2026.
- How has Tango Therapeutics's unrealized gains on investments changed year-over-year?
- Tango Therapeutics's unrealized gains on investments decreased by 91.4% year-over-year, from $221K to $19K.
- What is the long-term trend for Tango Therapeutics's unrealized gains on investments?
- Over 5 years (2020 to 2025), Tango Therapeutics's unrealized gains on investments has grown at a 67.5% compound annual growth rate (CAGR), from $17K to $224K.
Ask your AI about Tango Therapeutics's unrealized gains on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude